US 11,833,165 B2
Synthetic composition and method for treating irritable bowel syndrome
Thierry Hennet, Otelfingen (CH); Bruce McConnell, La Tour de Peilz (CH); Emma Elison, Hjärup (SE); and Louise Kristine Vigsnæs, København NV (DK)
Assigned to GLYCOM A/S, Hørsholm (DK)
Filed by Glycom A/S, Hørsholm (DK)
Filed on Jun. 7, 2021, as Appl. No. 17/341,039.
Application 17/341,039 is a continuation of application No. 15/897,099, filed on Feb. 14, 2018, granted, now 11,026,959.
Application 15/897,099 is a continuation of application No. 15/034,593, abandoned, previously published as PCT/DK2015/050332, filed on Oct. 29, 2015.
Claims priority of application No. PA 2014 70663 (DK), filed on Oct. 29, 2014.
Prior Publication US 2021/0308158 A1, Oct. 7, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/702 (2006.01); A61K 31/7004 (2006.01); A61K 31/7012 (2006.01); A61P 1/04 (2006.01); A23L 33/21 (2016.01); A23C 9/20 (2006.01)
CPC A61K 31/702 (2013.01) [A23C 9/206 (2013.01); A23L 33/21 (2016.08); A61K 31/7004 (2013.01); A61K 31/7012 (2013.01); A61P 1/04 (2018.01); A23V 2002/00 (2013.01)] 19 Claims
 
1. A method comprising:
selecting a non-infant human patient with irritable bowel syndrome (IBS) experiencing one or more IBS symptoms;
selecting an amount of one or more neutral human milk oligosaccharides (HMOs) selected from the group consisting of 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose I (LNFP-I), lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), and combinations thereof, the amount effective for increasing a relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of the non-infant human patient; and
increasing the relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of the non-infant human patient and reducing the likelihood of the non-infant human patient experiencing the one or more IBS symptoms by administering a daily dose of the selected amount of the one or more neutral HMOs to the non-infant human patient, wherein the daily dose is from about 2.5 g to about 10 g.